Yong Zhu

639 Longmian Avenue
Nanjing, 211198, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Design, Synthesis, and Biological Evaluation of Novel 1H‑Imidazo[4,5-g]quinazoline-Based SOS1::KRASG12C Inhibitors in Colorectal Cancer Cells.

Design, Synthesis, and Biological Evaluation of Novel 1H‑Imidazo[4,5-g]quinazoline-Based SOS1::KRASG12C Inhibitors in Colorectal Cancer Cells.

Journal: ACS medicinal chemistry letters

Published: December 16, 2025

Design and Synthesis of Novel N-(1H-pyrazol-3-yl)pyrimidin-4-amine Aurora/HDAC Dual Inhibitors for Colorectal Cancer Treatment.

Design and Synthesis of Novel N-(1H-pyrazol-3-yl)pyrimidin-4-amine Aurora/HDAC Dual Inhibitors for Colorectal Cancer Treatment.

Journal: Journal of medicinal chemistry

Published: November 10, 2025

Risk factors, microbiological resistance, and prognostic scoring in Fournier's gangrene: a retrospective cohort study.

Risk factors, microbiological resistance, and prognostic scoring in Fournier's gangrene: a retrospective cohort study.

Journal: BMC infectious diseases

Published: November 08, 2025

Close and Enhance the Cancer-Immunity Cycle by Engineered Dual-Targeted Nano-Adaptors.

Close and Enhance the Cancer-Immunity Cycle by Engineered Dual-Targeted Nano-Adaptors.

Journal: Advanced materials (Deerfield Beach, Fla.)

Published: October 29, 2025

Visible-light-promoted photoredox synthesis of thioacetylenes by dehydrogenation coupling of thiophenols and alkynes.

Visible-light-promoted photoredox synthesis of thioacetylenes by dehydrogenation coupling of thiophenols and alkynes.

Journal: RSC advances

Published: August 02, 2025

Targeting NF-κB-inducing kinase (NIK) in the non-canonical pathway: Advances in the development of NIK inhibitors.

Targeting NF-κB-inducing kinase (NIK) in the non-canonical pathway: Advances in the development of NIK inhibitors.

Journal: Bioorganic chemistry

Published: July 10, 2025

Structure-Guided Optimization of 2-Aminoquinazoline Hematopoietic Progenitor Kinase 1 Inhibitors for Improved Oral Bioavailability and Synergistic Antitumor Immunity.

Structure-Guided Optimization of 2-Aminoquinazoline Hematopoietic Progenitor Kinase 1 Inhibitors for Improved Oral Bioavailability and Synergistic Antitumor Immunity.

Journal: Journal of medicinal chemistry

Published: May 05, 2025

Targeting KRASG12C Mutation: Development of effective strategies to overcome drug resistance and limited efficacy.

Targeting KRASG12C Mutation: Development of effective strategies to overcome drug resistance and limited efficacy.

Journal: European journal of medicinal chemistry

Published: February 28, 2025

Uncovering the mechanism of Buyang Huanwu Decoction in regulating mitochondrial dysfunction to alleviate atherosclerosis: BTK, PREPL, and P2RX7 proteins play key roles.

Uncovering the mechanism of Buyang Huanwu Decoction in regulating mitochondrial dysfunction to alleviate atherosclerosis: BTK, PREPL, and P2RX7 proteins play key roles.

Journal: International journal of biological macromolecules

Published: January 21, 2025

Mechanistic study of a triterpenoid-enriched fraction derived from Cynomorium songaricum against NAFLD: An integrative elucidation.

Mechanistic study of a triterpenoid-enriched fraction derived from Cynomorium songaricum against NAFLD: An integrative elucidation.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: January 17, 2025

Key proteins identification of Buyang Huanwu Decoction in regulating macrophage polarization to alleviate atherosclerosis via an integrated strategy combining network pharmacology, batch molecular docking and experimental verification.

Key proteins identification of Buyang Huanwu Decoction in regulating macrophage polarization to alleviate atherosclerosis via an integrated strategy combining network pharmacology, batch molecular docking and experimental verification.

Journal: International journal of biological macromolecules

Published: January 08, 2025

Discovery of N-Phenyl-5-propyl-1H-pyrazole-3-carboxamide, with Selective Inhibition and Degradation of HDAC6 for the Treatment of Acute Liver Injury.

Discovery of N-Phenyl-5-propyl-1H-pyrazole-3-carboxamide, with Selective Inhibition and Degradation of HDAC6 for the Treatment of Acute Liver Injury.

Journal: Journal of medicinal chemistry

Published: December 16, 2024

Showing 1-12 of 38

Last Updated: 09/26/2026